These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27052879)

  • 1. Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.
    Bohnert T; Patel A; Templeton I; Chen Y; Lu C; Lai G; Leung L; Tse S; Einolf HJ; Wang YH; Sinz M; Stearns R; Walsky R; Geng W; Sudsakorn S; Moore D; He L; Wahlstrom J; Keirns J; Narayanan R; Lang D; Yang X;
    Drug Metab Dispos; 2016 Aug; 44(8):1399-423. PubMed ID: 27052879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reaction phenotyping to assess victim drug-drug interaction risks.
    Di L
    Expert Opin Drug Discov; 2017 Nov; 12(11):1105-1115. PubMed ID: 28820269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
    Iga K; Kiriyama A
    J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System.
    El-Kattan AF; Varma MV; Steyn SJ; Scott DO; Maurer TS; Bergman A
    Pharm Res; 2016 Dec; 33(12):3021-3030. PubMed ID: 27620173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America.
    Grimm SW; Einolf HJ; Hall SD; He K; Lim HK; Ling KH; Lu C; Nomeir AA; Seibert E; Skordos KW; Tonn GR; Van Horn R; Wang RW; Wong YN; Yang TJ; Obach RS
    Drug Metab Dispos; 2009 Jul; 37(7):1355-70. PubMed ID: 19359406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions.
    Kimoto E; Obach RS; Varma MVS
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):18-29. PubMed ID: 31952912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes.
    Zientek MA; Youdim K
    Drug Metab Dispos; 2015 Jan; 43(1):163-81. PubMed ID: 25297949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium.
    Tweedie D; Polli JW; Berglund EG; Huang SM; Zhang L; Poirier A; Chu X; Feng B;
    Clin Pharmacol Ther; 2013 Jul; 94(1):113-25. PubMed ID: 23588318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.
    Nettleton DO; Einolf HJ
    Curr Top Med Chem; 2011; 11(4):382-403. PubMed ID: 21320066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
    Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
    Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A perspective on the contribution of metabolites to drug-drug interaction potential: the need to consider both circulating levels and inhibition potency.
    Yu H; Tweedie D
    Drug Metab Dispos; 2013 Mar; 41(3):536-40. PubMed ID: 23143892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of non-human primates in drug development: Comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes.
    Uno Y; Uehara S; Yamazaki H
    Biochem Pharmacol; 2016 Dec; 121():1-7. PubMed ID: 27318253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactions and enzymes in the metabolism of drugs and other xenobiotics.
    Testa B; Pedretti A; Vistoli G
    Drug Discov Today; 2012 Jun; 17(11-12):549-60. PubMed ID: 22305937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative evaluation of drug-drug interaction potentials by in vivo information- guided prediction approach.
    Chen F; Hu ZY; Jia WW; Lu JT; Zhao YS
    Curr Drug Metab; 2014; 15(8):761-6. PubMed ID: 25705907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group.
    Yu H; Balani SK; Chen W; Cui D; He L; Humphreys WG; Mao J; Lai WG; Lee AJ; Lim HK; MacLauchlin C; Prakash C; Surapaneni S; Tse S; Upthagrove A; Walsky RL; Wen B; Zeng Z
    Drug Metab Dispos; 2015 Apr; 43(4):620-30. PubMed ID: 25655830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory Guidance.
    Schadt S; Bister B; Chowdhury SK; Funk C; Hop CECA; Humphreys WG; Igarashi F; James AD; Kagan M; Khojasteh SC; Nedderman ANR; Prakash C; Runge F; Scheible H; Spracklin DK; Swart P; Tse S; Yuan J; Obach RS
    Drug Metab Dispos; 2018 Jun; 46(6):865-878. PubMed ID: 29487142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In silico prediction models of the induction of drug-metabolizing enzymes for drug discovery].
    Yoshinari K; Nagai M
    Nihon Yakurigaku Zasshi; 2019; 153(4):186-191. PubMed ID: 30971659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Drug-Drug Interactions Related to Inhibition or Induction of Drug-Metabolizing Enzymes.
    Dmitriev AV; Lagunin AA; Karasev DА; Rudik AV; Pogodin PV; Filimonov DA; Poroikov VV
    Curr Top Med Chem; 2019; 19(5):319-336. PubMed ID: 30674264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PreMetabo: An in silico phase I and II drug metabolism prediction platform.
    Hwang S; Shin HK; Shin SE; Seo M; Jeon HN; Yim DE; Kim DH; No KT
    Drug Metab Pharmacokinet; 2020 Aug; 35(4):361-367. PubMed ID: 32616370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.